drugset / Trial / NCT03983967

Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

NCT03983967

Phase 1/2 Completed 19 enrolled GC Cell Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate and validate the maximum tolerated dose (MTD) or maximum available dose (MFD), safety and efficacy on patients with hepatocellular carcinoma beyond Milan criteria who undergo liver transplantation.

Timeline

Start
2019-01-24
Primary completion
2021-09-09
Completion
2022-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Immuncell-LC Cell therapy

Indications

No indication recorded.